Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
CONCLUSIONS: Biological and behavioral phenotypes elucidate human obesity heterogeneity and can be targeted pharmacologically to enhance weight loss.PMID:33759389 | DOI:10.1002/oby.23120 (Source: Obesity)
Source: Obesity - March 24, 2021 Category: Eating Disorders & Weight Management Authors: Andres Acosta Michael Camilleri Barham Abu Dayyeh Gerardo Calderon Daniel Gonzalez Alison McRae William Rossini Sneha Singh Duane Burton Matthew M Clark Source Type: research
Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
CONCLUSIONS: Biological and behavioral phenotypes elucidate human obesity heterogeneity and can be targeted pharmacologically to enhance weight loss.PMID:33759389 | DOI:10.1002/oby.23120 (Source: Obesity)
Source: Obesity - March 24, 2021 Category: Eating Disorders & Weight Management Authors: Andres Acosta Michael Camilleri Barham Abu Dayyeh Gerardo Calderon Daniel Gonzalez Alison McRae William Rossini Sneha Singh Duane Burton Matthew M Clark Source Type: research
Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
CONCLUSIONS: Biological and behavioral phenotypes elucidate human obesity heterogeneity and can be targeted pharmacologically to enhance weight loss.PMID:33759389 | DOI:10.1002/oby.23120 (Source: Obesity)
Source: Obesity - March 24, 2021 Category: Eating Disorders & Weight Management Authors: Andres Acosta Michael Camilleri Barham Abu Dayyeh Gerardo Calderon Daniel Gonzalez Alison McRae William Rossini Sneha Singh Duane Burton Matthew M Clark Source Type: research
Supraventricular tachycardia with the use of phentermine: case report and review of literature
Postgrad Med. 2021 Mar 9. doi: 10.1080/00325481.2021.1901476. Online ahead of print.ABSTRACTA 34-year-old woman with no significant past medical history presented to the hospital with sudden onset of palpitations with associated dyspnea and chest discomfort. She denied any similar previous episodes. Initial electrocardiogram (EKG) was consistent with a short R-P interval supraventricular tachycardia (SVT). Her transthoracic echocardiogram (TTE) revealed no structural abnormalities, TSH levels were normal, and urine drug screen was negative for any recreational drugs. The only medication she was taking at home was phentermi...
Source: Postgraduate Medicine - March 9, 2021 Category: Internal Medicine Authors: Sundeep Kumar Akhil Mogalapalli Ruthvik Srinivasamurthy Sayed T Hussain Philip Mar Source Type: research
Effects of Orlistat/Phentermine versus Phentermine on Vascular Endothelial Cell Function in Obese and Overweight Adults: A Randomized, Double-Blinded, Placebo-Controlled Trial
(Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy)
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - March 1, 2021 Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Obesity Pharmacotherapy is Effective in the Veterans Affairs Patient Population: A Local and Virtual Cohort Study.
CONCLUSIONS: Obesity pharmacotherapy is effective in achieving clinically meaningful weight loss in veterans as part of an integrated care approach.
PMID: 33491308 [PubMed - in process] (Source: Obesity)
Source: Obesity - January 27, 2021 Category: Eating Disorders & Weight Management Authors: Pendse J, Vallejo-García F, Parziale A, Callanan M, Tenner C, Alemán JO Tags: Obesity (Silver Spring) Source Type: research
Long-term effects of weight-reducing drugs in people with hypertension.
CONCLUSIONS: In people with elevated blood pressure, orlistat, phentermine/topiramate and naltrexone/bupropion reduced body weight; the magnitude of the effect was greatest with phentermine/topiramate. In the same trials, orlistat and phentermine/topiramate, but not naltrexone/bupropion, reduced blood pressure. One RCT of naltrexone/bupropion versus placebo showed no differences in all-cause mortality or cardiovascular mortality or morbidity after two years. The European Medicines Agency refused marketing authorisation for phentermine/topiramate due to safety concerns, while for lorcaserin the application for European mark...
Source: Cochrane Database of Systematic Reviews - January 17, 2021 Category: General Medicine Authors: Siebenhofer A, Winterholer S, Jeitler K, Horvath K, Berghold A, Krenn C, Semlitsch T Tags: Cochrane Database Syst Rev Source Type: research
Patterns of Weight Loss Medication Utilization and Outcomes Following Bariatric Surgery
ConclusionsRYGB patients respond better to WLM than SG patients. Those who had started WLM before regaining weight (AWL) experienced greater overall weight loss, suggesting that proactive medical therapy at the time of weight plateau can help with greater total weight loss. Phentermine + topiramate is the most effective WLM in post-bariatric surgery patients. (Source: Journal of Gastrointestinal Surgery)
Source: Journal of Gastrointestinal Surgery - January 8, 2021 Category: Surgery Source Type: research
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.
Authors: Son JW, Kim S
Abstract
Obesity is among the leading causes of morbidity and mortality worldwide and its prevalence continues to increase globally. Because obesity is a chronic, complex, and heterogeneous disease influenced by genetic, developmental, biological, and environmental factors, it is necessary to approach obesity with an integrated and comprehensive treatment strategy. As it is difficult to achieve and sustain successful long-term weight loss in most patients with obesity through lifestyle modifications (e.g., diet, exercise, and behavioral therapy), pharmacological approaches to the tre...
Source: Diabetes and Metabolism Journal - January 6, 2021 Category: Endocrinology Tags: Diabetes Metab J Source Type: research
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
AbstractPurpose of ReviewAs a chronic and relapsing disease, obesity impairs metabolism and causes cardiovascular diseases. Although behavioral modification is important for the treatment of obesity, it is difficult to achieve an ideal weight or sustain the process of long-term weight loss. Therefore, the obesity control guidelines strongly recommend lifestyle interventions along with medical treatment for patients who are overweight. There is sufficient evidence supporting that pharmacotherapy in combination with behavior-based interventions can result in significant weight loss and improved cardiometabolism.Recent Findin...
Source: Current Obesity Reports - January 6, 2021 Category: Eating Disorders & Weight Management Source Type: research
Pharmacotherapy in pediatric obesity: current evidence and landscape
Purpose of review
Childhood obesity is escalating globally. Lifestyle and behavioral changes, which are the frequently used interventions in clinical practice, lead to only modest improvements in children with established obesity. Bariatric surgery is currently the most effective obesity treatment but has very limited utilization in pediatric obesity and is preferentially used for children with worsening comorbidities. There exists a massive treatment gap for children suffering with obesity especially after the failure of lifestyle modifications. Pharmacotherapy that is an established management tool in adults is very ...
Source: Current Opinion in Endocrinology, Diabetes and Obesity - December 26, 2020 Category: Endocrinology Tags: GROWTH AND DEVELOPMENT: Edited by Lynne L. Levitsky Source Type: research
Scleroderma in the Setting of Long-term Intermittent Phentermine Use.
Authors: Beer J, Maderal A
PMID: 33196751 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Trends in prescribing anti ‐obesity pharmacotherapy for paediatric weight management: Data from the POWER Work Group
ConclusionsThese data suggest the need for (a) additional robust paediatric drug trials to further develop the evidence base guiding use or non ‐use of pharmacotherapy in paediatric weight management, and (b) increased understanding of both facilitators and barriers to prescribing anti‐obesity pharmacotherapy for youth with obesity. (Source: Pediatric Obesity)
Source: Pediatric Obesity - September 1, 2020 Category: Eating Disorders & Weight Management Authors: Claudia Borzutzky,
Eileen King,
Claudia K Fox,
William Stratbucker,
Jared Tucker,
Jennifer K Yee,
Seema Kumar,
Suzanne Cuda,
Brooke Sweeney,
Shelley Kirk,
on behalf of the POWER Work Group Tags: ORIGINAL RESEARCH Source Type: research
The risk of cardiovascular complications with current obesity drugs.
Authors: Chao AM, Wadden TA, Berkowitz RI, Quigley K, Silvestry F
Abstract
INTRODUCTION: Obesity is associated with an increased risk of cardiovascular morbidity and mortality. Four medications are approved by the US Food and Drug Administration (FDA) for chronic weight management when used as an adjunct to a reduced-calorie diet and increased physical activity in adults. These medications result in clinically significant weight losses, as well as improvements in some cardiometabolic risk factors.
AREAS COVERED: We briefly review the history of anti-obesity medications (AOMs) as related to cardiova...
Source: Expert Opinion on Drug Safety - August 13, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
